A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-Label Extension.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-Label Extension.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Risperidone (Primary)
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 26 Jan 2009 Patient number amended from 554 to 559 as reported by ClinicalTrials.gov.
    • 26 Oct 2008 Actual patient number (564) added as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Actual end date added (Dec 2007) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top